Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual MeetingRAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's primary endpoint
- Alveus Therapeutics Initiates Phase 2 PRESERVE Trial to Evaluate ALV-100 for Chronic Weight ManagementAlveus Therapeutics Inc. (“Alveus”), a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases, today announced the initiation of the Phase 2 PRESERVE trial and dosing of the first patient with ALV-100, its lead investigational therapy designed to address one of the most important unmet needs in obesity care: sustaining weight loss over time. The study will evaluate ALV-100 in adults with obesity or overweight who have achieved and stabilized their weight loss with semaglutide and are transitioning to long-term weight management.
- Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of AnaphylaxisClinical study to evaluate NS002, the Company's investigational intranasal epinephrine powder, as a needle-free alternative to EpiPen® for patients experiencing anaphylaxis and will compare self-administration to administration by a health care professional
- Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma ModelsTelomir Pharmaceuticals announces Ohio State research demonstrating Telomir-Zn inhibition of cell growth across human and canine osteosarcoma models.
- OrganonOrganon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine DeviceJERSEY CITY, N.J., September 14, 2026--Organon announces FDA accepts MIUDELLA® sNDA for review, seeking to extend approved hormone-free IUD use from 3 to 6 years in the U.S.
- Lysoway Therapeutics Announces Preclinical Data Supporting First-in-Class TRPML1 Agonist LW-1017 in Scientific ReportsCAMBRIDGE, Mass., September 14, 2026--Lysoway Therapeutics, a clinical-stage biotechnology company pioneering therapeutics targeting lysosomal ion channels for age-related neurodegenerative diseases, today announced the publication of preclinical data evaluating its lead candidate, LW-1017, in Scientific Reports, a journal from Nature Portfolio.
- Seaport Therapeutics, Inc.Seaport Therapeutics to Participate in September Investor ConferencesBOSTON, September 14, 2026--Seaport Therapeutics, Inc. (Nasdaq: SPTX) ("Seaport" or the "Company"), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced that members of its management team will participate in a series of additional upcoming investor conferences in September, including a company presentation and panel discussion featuring Co-Founder and Chief Executive Officer, Daphne Zohar, at the Goldman Sachs Life Sciences Sym
- Definium Therapeutics, Inc.Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety DisorderNEW YORK, September 14, 2026--Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced positive topline results from Panorama, the Company’s second Phase 3 study of DT120 (lysergide) Orally Disintegrating Tablet (ODT) in adults with generalized anxiety disorder (GAD). This is the Company’s thi
- Exosome Therapies Market Poised for Significant Growth Through 2036 as Expanding Target Populations and Biopharma Innovation Create New OpportunitiesExosome therapies offer broad regenerative and targeted-delivery potential, while standardization, scalability and regulatory hurdles create key innovation opportunities.
- BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer PatientsMAINZ, Germany, and — BioNTech SE (Nasdaq: BNTX, “BioNTech”) and OncoC4, Inc. (“OncoC4”) today announced the first median overall survival (“OS”) data from the non-pivotal stage 1 of the global randomized PRESERVE-003 Phase 3 clinical trial (NCT05671510) of gotistobart (also known as BNT316 or ONC-392), in patients with squamous non-small lung cancer (“NSCLC”) whose disease progressed on prior immunotherapy and chemotherapy. Gotistobart is an investigational CTLA-4-targeting immunotherapy designed to selectively deplete regulatory T cells (“Tregs”) within the tumor microenvironment and restore anti-tumor immune activity.
- Abe Yoando Pharma Co., Ltd.Tomonari Abe, President of Abe Yoando Pharma, Selected as First Japanese Speaker at Longevity Investors Conference 2026 in Switzerland- Head of 295-year-old Japanese Pharmaceutical Pioneer to Present Asia's Longevity Growth Strategies and Bioscientific Research Initiatives at Prestigious Conference - — Abe Yoando Pharma Co., Ltd., a nearly 300-year-old...
- NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung CancerData presented at the IASLC 2026 World Conference on Lung Cancer